# KEYNOTE-811 (NCT03615326)

> Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus trastuzumab
- Indication: first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03615326
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma
- Interventions: Pembrolizumab; Placebo; Cisplatin; 5-FU; Oxaliplatin; Capecitabine; S-1; Trastuzumab
- Enrollment: 738
- Primary outcome: Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR
- Primary outcome: Overall Survival (OS)

## Questions raised in the commentary

_Automated from the 40 newest of 292 indexed sources (May 2026 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether KEYNOTE-811 remains an appropriate option alongside newer first-line regimens
- How to interpret comparisons between KEYNOTE-811 and zanidatamab regimens without direct comparative evidence
- Whether PD-L1 expression identifies patients who benefit from pembrolizumab

Also discussed: biomarker testing access.

## Indexed commentary on KEYNOTE-811 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 117
- Podcasts: 99
- X threads: 73
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-811-nct03615326

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03615326", "email": "<work email>"}; the inbox owner confirms by the emailed link.